You are here

Article Text

Article menu
Download PDFPDF
Chairmen's introduction
pH-Hp: implications for dyspepsia management
  1. A Axon,
  2. N J Talley,
  3. S J O Veldhuyzen van Zanten
  1. 1Centre for Digestive Diseases, General Infirmary at Leeds, Leeds, UK
  2. 2Department of Medicine, University of Sydney, Nepean Hospital, Penrith, Australia
  3. 3Division of Gastroenterology, Dalhousie University, Halifax, Nova Scotia, Canada
  1. Correspondence to:
    Professor A T R Axon, Gastroenterology Unit, General Infirmary, Great George Street, Leeds LS1 3EX, UK;
    anthonya{at}ulth.northy.nhs.uk

https://doi.org/10.1136/gut.50.suppl_4.iv1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction to the proceedings of the symposium on dyspepsia management, held in Geneva, Switzerland, December 1998.

    Clinical trials using omeprazole began in 1983. Research since then, involving more than 50 000 patients, has shown that this drug is safe and well tolerated. It is consistently effective in the treatment of peptic ulcer disease and gastro-oesophageal reflux disease. It plays a pivotal role in the treatment of Helicobacter pylori infection. It is also valuable in prophylaxis for patients taking non-steroidal anti-inflammatory drugs and in the intensive care unit for stress ulcer prophylaxis. For all of these reasons, …

    View Full Text